IPSEN SA S/ADR - IPSEY STOCK NEWS

IPSEN announced details of share transactions aggregating significant trading data. On June 27, 2022, the company acquired 6,950 shares at a weighted average price of €85.0020, with additional transactions on June 29 totaling 776 shares at an average price of €85.3929. The total volume of shares acquired across these days reached 7,726 at an average price of €85.0413. These transactions were executed on the XPAR and CEUX platforms, indicating ongoing strategic movements in shareholding.

Ipsen announced that the FDA has accepted for Priority Review its resubmitted NDA for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (FOP). This acceptance signifies a critical step for patients with FOP, as there are currently no approved treatments. The Prescription Drug User Fee Act goal date is set for December 29, 2022. Palovarotene has already been approved in Canada and is undergoing review in the EU. Ipsen emphasizes its commitment to developing innovative treatments for rare diseases despite regulatory challenges.

IPSEN reported significant trading activity with a total of 8,762 shares exchanged between June 20 and June 23, 2022. The daily weighted average price ranged from 82.7186 to 84.1235, with an overall average of 83.1677. This trading data was sourced from the XPAR platform. The report details individual transactions, emphasizing the total volume and average pricing during the specified period, which is critical for investors monitoring stock performance.

Ipsen announced the acquisition of Epizyme for an all-cash tender offer at $1.45 per share, plus a contingent value right of $1.00 per share. The deal, unanimously approved by both boards, aims to enhance Ipsen's oncology portfolio by focusing on Tazverik^®, an EZH2 inhibitor approved for treating specific types of lymphoma. Ipsen anticipates that the acquisition will strengthen its market presence in oncology, despite expected moderate dilution in core operating income until the end of 2024.

Ipsen announced a definitive merger agreement to acquire Epizyme, focusing on Tazverik® (tazemetostat), an EZH2a inhibitor approved in the U.S. The acquisition involves an all-cash tender offer of $1.45 per share and a contingent value right (CVR) of $1.00 per share. Anticipating closure by Q3 2022, this deal enhances Ipsen’s oncology portfolio, aiming for increased sales and leveraging existing infrastructure. The transaction is expected to be moderately dilutive to Ipsen’s core operating income until 2024. Royalty Pharma, holding 20.5% of Epizyme shares, supports the acquisition.

IPSEN has reported its aggregated share acquisition data for the week of June 13-17, 2022. During this period, the company acquired a total of 27,390 shares at a daily weighted average price of €83.6876. The highest daily acquisitions occurred on June 13 with 7,500 shares at an average price of €86.2925, while the lowest was on June 15 with 2,500 shares priced at €84.1820. This information is crucial for investors monitoring IPSEN's share buyback activities.

IPSEN has released a regulatory update detailing the aggregated share transactions conducted on the XPAR platform. On June 6, 2022, a total of 3,500 shares were acquired at a daily weighted average price of €93.7123. Cumulatively, 18,500 shares have been transacted at an average price of €91.8285. The report underlines the company's active share management and compliance with market regulations, emphasizing transparency in financial operations.

Ipsen has reported the total number of shares composing its share capital as of May 31, 2022, which stands at 83,814,526 shares. The gross total of voting rights is 132,125,928, while the net total is 131,073,533. This report aligns with the French Commercial Code regulations.

The net total excludes shares without voting rights, ensuring compliance with statutory obligations concerning threshold crossing declarations.

Ipsen has received a positive opinion in Europe for Dysport® (abobotulinumtoxinA) aimed at treating urinary incontinence in adults with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. This approval allows individual European countries to grant national approvals. Dysport® showed significant improvements in clinical trials, reducing incontinence episodes and enhancing bladder capacity. The CONTENT Phase III trial included 485 patients and demonstrated Dysport®'s efficacy in managing symptoms inadequately controlled by oral therapies.